Department of Pathology, Boston Children's Hospital, Boston, MA, USA.
Department of Pathology, Massachusetts General Hospital, Boston, MA, USA.
Semin Hematol. 2019 Jan;56(1):15-21. doi: 10.1053/j.seminhematol.2018.05.015. Epub 2018 Jun 23.
Myelodysplastic syndromes (MDS) are heterogeneous hematopoietic neoplasms that share key clinical and biologic features, including peripheral blood cytopenias, morphologic dysplasia, ineffective and clonal hematopoiesis, and a variable risk of transformation to acute myeloid leukemia. Diagnostic evaluation of MDS relies on morphologic assessment of the peripheral blood and bone marrow, conventional cytogenetics, and exclusion of secondary causes of dysplasia. The diagnosis of MDS has important clinical consequences, but it can be challenging and requires distinction from mimics. In this review, the principles of bone marrow interpretation with respect to the diagnosis and classification of MDS in the current era will be discussed, including accurate morphologic interpretation, use of flow cytometry and immunohistochemistry, appropriate use of cytogenetics, and the emerging role of molecular genetics.
骨髓增生异常综合征(MDS)是一组异质性造血肿瘤,具有一些关键的临床和生物学特征,包括外周血细胞减少、形态学发育异常、无效造血和克隆性造血,以及向急性髓系白血病转化的风险可变。MDS 的诊断评估依赖于外周血和骨髓的形态学评估、常规细胞遗传学以及排除继发于发育异常的原因。MDS 的诊断具有重要的临床意义,但可能具有挑战性,需要与模拟物相鉴别。在这篇综述中,将讨论在当前时代中,与 MDS 的诊断和分类相关的骨髓解读原则,包括准确的形态学解读、流式细胞术和免疫组织化学的应用、细胞遗传学的适当应用以及分子遗传学的新兴作用。